These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 5402903)

  • 1. [Action of aluminum bis-parachlorophenoxyisobutyrate (2CPIBA) on various hyperlipoproteinemias: initial results].
    Vastesaeger MM; Peeters H; Blaton V; Vanderveiken F; Vastesaeger E
    Brux Med; 1969 Oct; 49(10):615-29. PubMed ID: 5402903
    [No Abstract]   [Full Text] [Related]  

  • 2. [Association of neomycin sulfate and ethyl-p-chlorophenoxybutyrate in the treatment of dyslipemia].
    Bertulla A; Bertamino V; Solari E
    Ateneo Parmense 1; 1971; 42(2):103-14. PubMed ID: 5154400
    [No Abstract]   [Full Text] [Related]  

  • 3. Clofibrate and androsterone effect on serum lipids.
    Orgain ES; Bogdonoff MD; Cain C
    Arch Intern Med; 1967 Jan; 119(1):80-5. PubMed ID: 6015838
    [No Abstract]   [Full Text] [Related]  

  • 4. [Experience with 110 medium-length therapeutic trials of ethyl chlorophenoxyisobutyrate with or without androsterone in various types of idiopathic hyperlipidemia].
    De Gennes JL; Maunand B; Salmon D; Laudat P; Truffert J
    Rev Atheroscler (Paris); 1966; 8(1):27-52. PubMed ID: 5961027
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical evaluation of the antidyslipemic action of a sulfomucopolysaccharide of pancreatic origin].
    Svetoni N; D'Alonzo D; Rechichi A
    Clin Ter; 1974 Oct; 71(1):33-48. PubMed ID: 4279159
    [No Abstract]   [Full Text] [Related]  

  • 6. [Changes of the coefficient of peripheral utilization of glucose after venous administration, in hypercholesteremic subjects, after treatment with an antidyslipidemic agent].
    Pasini P
    G Gerontol; 1969 Aug; 17(8):808-16. PubMed ID: 5371744
    [No Abstract]   [Full Text] [Related]  

  • 7. Hyperlipoproteinemias in the prematurely aged. Theories of pathogenesis, diagnosis, classification, and treatment.
    Herrmann GR
    Geriatrics; 1970 Apr; 25(4):103-14. PubMed ID: 5443794
    [No Abstract]   [Full Text] [Related]  

  • 8. [Action of ethyl chlorophenoxyisobutyrate on several types of hyperlipidemia].
    Beaumont V; Swynghedauw B; Beaumont JL; Himbert J
    Rev Atheroscler (Paris); 1966; 8(1):12-20. PubMed ID: 5961026
    [No Abstract]   [Full Text] [Related]  

  • 9. [Antilipidemic activity of ethyl-chloro-phenoxy-isobutyrate or clofibrate].
    Barisone D; Gallo G; Accardo S
    Minerva Med; 1969 Jan; 60(6):174-80. PubMed ID: 5776766
    [No Abstract]   [Full Text] [Related]  

  • 10. [Differentiation and drug therapy of lipemias].
    Schettler G
    Dtsch Med J; 1968 Apr; 19(8):250-8. PubMed ID: 5728720
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of highly purified D-thyroxine ("Dyno") in hyperlipoproteinemias type II a and II b].
    von Löwis of Menar P; Klemens UH
    Verh Dtsch Ges Inn Med; 1972; 78():1623-5. PubMed ID: 4353152
    [No Abstract]   [Full Text] [Related]  

  • 12. Divergent effects in the treatment of hyperlipemia.
    Slowe IA; Carter AC; Feldman EB
    Arch Intern Med; 1965 Oct; 116(4):523-30. PubMed ID: 5835355
    [No Abstract]   [Full Text] [Related]  

  • 13. [Evaluation of the effects of tiadenol in various types of dyslipidemia].
    Saettone G; Cazzani E; Romanò M; Muzio L
    Clin Ter; 1982 May; 101(4):387-93. PubMed ID: 7105643
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical and biological trials of C.P.I.B.-aluminium].
    Jouve A; Avril P; Mary Y; Pierron J; Pons JC
    Mars Med; 1970; 107(8):575-88. PubMed ID: 5450599
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hypolipemic effects of a new tetralin derivative: compound 13473-Su (Ciba)].
    Ciobanu V; Zălaru MC; Ciocan A; Mihăilescu S
    Stud Cercet Med Interna; 1971; 12(1):67-80. PubMed ID: 5565781
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hyperlipidemias: occurrence, significance, therapy].
    Knüchel F
    Med Welt; 1967 Aug; 32():1848-60. PubMed ID: 5589916
    [No Abstract]   [Full Text] [Related]  

  • 17. [Importance of the clofibrat in the treatment of lipid metabolism disorders].
    Laubinger G
    Med Klin; 1968 Jan; 63(4):139-42. PubMed ID: 5670163
    [No Abstract]   [Full Text] [Related]  

  • 18. [Action mechanism and clinical success of Regelan (Clofibrate)].
    Fitzgerald JD
    Wien Klin Wochenschr; 1967 Sep; 79(39):716-20. PubMed ID: 5595437
    [No Abstract]   [Full Text] [Related]  

  • 19. [Studies on the effect of d-thyroxine in patients with increased serum lipid level].
    Steger H
    Wien Klin Wochenschr; 1968 Nov; 80(47):887-98. PubMed ID: 5717659
    [No Abstract]   [Full Text] [Related]  

  • 20. [Incidence of hyperlipoproteinemias in patients of the Ulm University Hospital].
    Klör U; Mertens HR; van Eimeren W; Wack HO; Ditschuneit HH; Ditschuneit H
    Verh Dtsch Ges Inn Med; 1972; 78():1349-52. PubMed ID: 4665543
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.